{
    "title": "Federal Research Product Commercialization Act",
    "content": "SECTION 1. SHORT TITLE.\n\n    This Act may be cited as the ``Federal Research Product \nCommercialization Act''.\n\nSEC. 2. ESTABLISHMENT OF PROCESS REGARDING REASONABLE PRICES FOR \n              PRODUCTS DEVELOPED AS CONSEQUENCE OF FUNDING BY NATIONAL \n              INSTITUTES OF HEALTH.\n\n    Part G of title IV of the Public Health Service Act (42 U.S.C. 289 \net seq.) is amended by inserting after section 498 the following \nsection:\n\n     ``reasonable prices for products developed with assistance of \n                               institutes\n\n    ``Sec. 498B. (a) In General.--Subject to the provisions of this \nsection, for fiscal year 1994 and subsequent fiscal years, a project of \nbiomedical research relating to the development of a drug, device, or \nother tangible product may not be conducted or supported by any agency \nof the National Institutes of Health unless there are in effect such \nregulations issued by the Secretary as may be necessary to ensure that, \nin the event the product is (in accordance with applicable law) to be \nmade available to the public, there is compliance with the following:\n            ``(1) The research entity, in accordance with this section, \n        will ensure that the commercial parties involved make the \n        product available to the public at a reasonable price, and that \n        the commercial parties pay to the National Institutes of Health \n        royalties reasonably related to the amounts expended by such \n        Institutes with respect to the product.\n            ``(2) For purposes of paragraph (1), the research entity \n        will conduct a competitive process of bidding in order to \n        select entities to serve as commercial parties regarding the \n        product. With respect to such bidding, a solicitation of \n        applications containing bids will be published in the Federal \n        Register.\n            ``(3) Applicants under paragraph (2) will not be approved \n        by the research entity as commercial parties regarding the \n        project unless the following conditions are met:\n                    ``(A) The application specifies a formula for \n                determining the price at which the product will be made \n                available to the public, and the formula results in a \n                price that is in accordance with paragraph (1).\n                    ``(B) The application specifies the royalties to be \n                paid to the National Institutes of Health, and the \n                royalties are in accordance with paragraph (1).\n                    ``(C) The application demonstrates that the \n                applicant possesses the appropriate biomedical and \n                commercial expertise.\n                    ``(D) The application is in such form, is made in \n                such manner, and contains such other information as the \n                Secretary may require.\n            ``(4)(A) Subject to subparagraph (B), in selecting \n        commercial parties under paragraph (3), the research entity \n        will, if there are a sufficient number of qualified applicants, \n        approve such applications as may be necessary to ensure that \n        commercial parties compete in making the product available to \n        the public.\n            ``(B) The research entity will comply with subparagraph (A) \n        only to the extent not inconsistent with paragraph (1).\n            ``(5)(A) If there is an insufficient number of qualified \n        applicants to provide for competing commercial parties, the \n        research entity will, in approving applications to provide for \n        an exclusive arrangement for making the product available to \n        the public, require that the applicants negotiate prices and \n        royalties under paragraph (1) with the Secretary.\n            ``(B) If an exclusive arrangement under subparagraph (A) is \n        to be made, the Secretary will publish in the Federal Register \n        a notice of such fact.\n            ``(C) An exclusive arrangement under subparagraph (A) will \n        not become legally binding until the expiration of the 90-\n        period beginning on the date on which the notice required in \n        subparagraph (B) with respect to the arrangement is published \n        in the Federal Register.\n    ``(b) Applicability.--Subsection (a) applies with respect to a \ndrug, device, or other tangible product only if the project of research \ninvolved provides a material contribution to achieving status as a \ndrug, device, or other product that, under applicable law, is permitted \nto be made available to the public.\n    ``(c) Required Agreements.--With respect to a project of research \ndescribed in subsection (a), regulations under such subsection shall, \nin the case of the non-Federal entities involved, impose the \nrequirements of this section as required agreements between such \nentities and the National Institutes of Health, including (if the \nproject is supported by such Institutes) imposing the requirements as \nconditions of the receipt from such Institutes of the award of the \ngrant, cooperative agreement, or contract for the conduct of the \nproject. Conditions for such awards shall, as necessary, include \nconditions governing the arrangements that the research entity involved \nmakes with entities to serve as commercial parties regarding the drug, \ndevice, or other tangible product involved, without regard to whether \nthe National Institutes of Health is a direct party to such \narrangements.\n    ``(d) Consultations Regarding Regulations.--In issuing regulations \npursuant to subsection (a), the Secretary shall consult with the \nDirector of NIH and with the Administrator of the Health Care Financing \nAdministration.\n    ``(e) Definitions.--For purposes of this section:\n            ``(1) The term `commercial parties' means the parties that \n        make available to the public a drug, device, or other tangible \n        product.\n            ``(2) The term `make available', with respect to the use by \n        the public of a drug, device, or other tangible product, \n        means--\n                    ``(A) to manufacture the product; or\n                    ``(B) to sell or trade the product, or to offer to \n                sell or trade the product.\n            ``(3) The term `product' means a drug, device, or other \n        tangible product.\n            ``(4)(A) The term `research entity', with respect to \n        project of biomedical research described in subsection (a), \n        means the entity with the principal property interest in the \n        results of the research, without regard to whether the entity \n        is the National Institutes of Health or a non-Federal entity.\n            ``(B) An entity is a research entity under subparagraph (A) \n        without regard to whether the property interest in the results \n        of the project involved--\n                    ``(i) is directly in the drug, device, or other \n                product that is the subject of the project; or\n                    ``(ii) is only in findings that relate to the \n                product.''."
}